Last reviewed · How we verify
Erenumab 70 mg
At a glance
| Generic name | Erenumab 70 mg |
|---|---|
| Also known as | Aimovig |
| Sponsor | Amgen |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine Patients (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache (PHASE4)
- Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study (PHASE4)
- Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine (PHASE4)
- Biomarker and Genetic Predictors of Erenumab Treatment Response (PHASE4)
- Erenumab-aooe for Temporomandibular Disorders Management: TMD Cgrp Antibody RElief (TMD CARE) (PHASE2)
- Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBI (PHASE2)
- A Controlled Trial of Erenumab in Migraine Prevention (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Erenumab 70 mg CI brief — competitive landscape report
- Erenumab 70 mg updates RSS · CI watch RSS
- Amgen portfolio CI